Temporal changes in the clinical approach to diagnosing prostate cancer

about

Human papillomavirus 16 infection as a potential risk factor for prostate cancer: an adaptive meta-analysis.Epidemiological evidences on overdiagnosis of prostate and kidney cancers in Korean

P2860

Q35211033-C6F5BF07-F355-45A4-8F8E-0078D7D31913 Q35438683-B185FEA2-812A-4F8A-B012-510B57B0F678

P2860

Temporal changes in the clinical approach to diagnosing prostate cancer

Item

http://www.wikidata.org/entity/Q36520528

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Temporal changes in the clinical approach to diagnosing prostate cancer

@ast

Temporal changes in the clinical approach to diagnosing prostate cancer

@en

type

Item

label

Temporal changes in the clinical approach to diagnosing prostate cancer

@ast

Temporal changes in the clinical approach to diagnosing prostate cancer

@en

prefLabel

Temporal changes in the clinical approach to diagnosing prostate cancer

@ast

Temporal changes in the clinical approach to diagnosing prostate cancer

@en

P1476

Temporal changes in the clinical approach to diagnosing prostate cancer

@en

P2093

Ian M Thompson

http://www.w3.org/2001/XMLSchema#string

Robin J Leach

http://www.w3.org/2001/XMLSchema#string

Susan S Padalecki

http://www.w3.org/2001/XMLSchema#string

William M Hilton

http://www.w3.org/2001/XMLSchema#string

P2860

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

Cancer statistics, 2010

A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness

Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay.

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.

The influence of finasteride on the development of prostate cancer.

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection

Impact of age at diagnosis on prostate cancer treatment and survival

PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.

P304

162-168

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCIMONOGRAPHS/LGS038

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P50

Donna Ankerst

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233999944

http://www.w3.org/2001/XMLSchema#string

P698

23271768

http://www.w3.org/2001/XMLSchema#string

P932

3540883

http://www.w3.org/2001/XMLSchema#string

Temporal changes in the clinical approach to diagnosing prostate cancer

about

P2860

P2860

Temporal changes in the clinical approach to diagnosing prostate cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932